A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15).
Sun Kyung BaekJae-Ho JeongKyung Hae JungHee Kyung AhnMin Hwan KimJoohyuk SohnIn Hae ParkJin Seok AhnDae-Won LeeSeock-Ah ImSung Hoon SimKeun Seok LeeJee Hyun KimHyun-Jeong ShimYeesoo ChaeSu-Jin KohHyorak LeeJieun LeeJae-Ho ByunYoungmi SeolEun Mi LeeHee-Jung JeeHyonggin AnEun Byeol ParkYoung Ju SuhKyoung Eun LeeYeon Hee Parknull nullPublished in: Therapeutic advances in medical oncology (2024)
This is the first nationwide real-world study of T-DM1 use in patients with HER2-positive mBC in Korea. The effectiveness and toxicity profiles of T-DM1 in real-world practice were comparable to those in randomized trials. Moreover, patient factors and previous anti-HER2 therapy could predict the outcomes of T-DM1 therapy.